The global urinary tract infection market is anticipated to grow at a CAGR of 4.8% during the forecast period (2021-2027). The key factor to drive the market growth is the increasing prevalence of diabetes and obesity due to the adoption of unhealthy lifestyles and increasing addiction to alcohol and obesity in many countries. For instance, according to International Diabetes Association in 2019, Diabetes affects approximately 463 million people aged 20 to 79, with the number expected to increase to 700 million by 2045. Diabetes cost the US economy at least $760 billion in 2019, accounting for 10% of total adult spending. Further, Adult obesity rates now exceed 35% in 12 states, 30% in 35 states, and 25% in 48 states, according to the most recent Behavioural Risk Factor Surveillance System (BRFSS) data. Mississippi has the highest adult obesity rate (40.8%), while Colorado and Washington, DC have the lowest (23.8%). Between the years 2018 and 2019,
To Request a Sample of our Report on Global Urinary Tract Infection Market: https://www.omrglobal.com/request-sample/urinary-tract-infection-treatment-market
Rising acquisitions, product approval, collaborations among the major players if the market also propel the growth of the market. For instance, in July 2019, Recarbrioan antibacterial drug product has been approved by the US Food and Drug Administration (FDA) to treat adults with complicated urinary tract infections and complicated intra-abdominal infections. With this approval The FDA is committed to encouraging the production of new antibacterial drugs that are both safe and reliable, giving patients more choices in the battle against severe infections.
Market Coverage
· The market number available for – 2020-2027
· Base year- 2020
· Forecast period- 2021-2027
Ø Segment Covered-
· By Test Type
· By Indication
· By End-User
Ø Regions Covered-
· North America
· Europe
· Asia-Pacific
· Rest of the World
· Competitive Landscape- AstraZeneca PLC, Bayer AG, Danaher Corp., Becton, Dickinson and Co., Biotronik SE & Co. KG, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, Pfizer Inc., Siemens AG, and others.
Key questions addressed by the report
· What is the market growth rate?
· Which segment and region dominate the market in the base year?
· Which segment and region will project the fastest growth in the market?
· How COVID-19 impacted the market?
· Deviation from the pre-COVID-19 forecast
· Most affected region and segment
· Who is the leader in the market?
· How players are addressing challenges to sustain growth?
· Where is the investment opportunity?
(Get 15% Discount on Buying this Report)
A full Report of Global Urinary Tract Infection Market is Available at: https://www.omrglobal.com/industry-reports/urinary-tract-infection-treatment-market
Global Urinary Tract Infection Market Report Segment
BY Test Type
· Biochemical Urinary Tract Infection
· Microscopic Urinary Tract Infection
· Flow Cytometric Urinary Tract Infection
By Indication
· Complicated Urinary Tract Infection
· Uncomplicated Urinary Tract Infection
· Neurogenic Bladder Infections
By End-User
· Hospitals and Clinics
· Home Healthcare
(This release has been published on Global Market Post. Global Market Post is not responsible for any content included in this release.)
